APGE
Apogee TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The best bull argument after the May 11, 2026 update is that Apogee kept a dense 2026 catalyst calendar intact while extending cash runway into 2029, through a planned AD BLA filing subject to regulatory alignment, and secondary coverage indicated Q1 EPS came in better than consensus.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -2.5.
What can break
APEX Part B is the next major proof point; a weaker-than-expected induction dataset could pressure the planned Phase 3 path in AD.
Momentum
60
Value
41
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $84.00 · Bull $112.00 · Bear $62.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $104.79
Why
Momentum60 · Δ7d -2.5
Value41 · Δ7d +0.1
Sentiment56 · Δ7d +5.6
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
60
34% active weight
Current posture
7d trendFlat
Δ7d
-2.5
Δ21d
-20.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
56
33% active weight
Current posture
7d trendImproving
Δ7d
+5.6
Δ21d
-5.5
Why this grade
Composite grade C. Momentum 60.0 / Value 41.1 / Sentiment 56.1
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$5.93B
Beta
-
Shares Out
54.83M
P/E (TTM) · Derived
-25.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-26.50
Rev YoY
-
EPS YoY
-28.2%
Gross Margin
-
Op Margin
-
Net Debt
-$520.65M
Current Ratio
15.86
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology